ACI 11th Summit on Biosimilars & Innovator Biologics

Meier Explains FTC's Power to Pursue Antitrust Activity

September 30, 2020

Article

The Federal Trade Commission's powers to bring antitrust actions are circumscribed by public versus private and what is vs isn't "reasonable," Markus H. Meier explained.

FTC's Markus H. Meier Talks About Restraint of Trade in the Biosimilar Marketplace

September 28, 2020

Article

Some acts by companies in the biologics marketplace may go too far in preventing free market activity, according to Markus H. Meier, acting director for the Federal Trade Commission (FTC) Bureau of Competition.

Biopharmaceutical Industry Representatives Discuss Product Hopping Legislation

September 24, 2020

Article

Two bills in Congress meant to address the anticompetitive practice of product hopping drew fire at the American Conference Institute's annual biosimilars conference.

FDA's Eva Temkin Discusses Biosimilar Approvals at ACI

September 23, 2020

Article

The FDA's Office of Therapeutic Biologics and Biosimilars balances a large number of biosimilar development projects with limited resources and is making progress, says Eva Temkin, acting director of policy.

California's Anticompetitive Legislation Is Scrutinized at ACI

September 23, 2020

Article

Panelists at American Conference Institute's (ACI) 2020 virtual summit discuss California's legislative attempts to improve competition in the drug industry.

Attorneys, Others Discuss Current Trends in Biosimilar Development

June 28, 2019

Article

Industry insiders discuss current trends about the patent dance and other issues, as well as proposed legislation that could affect biosimilar development.

Antitrust Issues Surrounding Biosimilars, Originator Products Not Going Away Anytime Soon

June 27, 2019

Article

Courts will be busy with biosimilar litigation for the foreseeable future, attorneys predicted at a panel on the second day of the ACI 10th Summit on Biosimilars.

What's New in the Biosimilar Labeling, Naming Landscape

June 26, 2019

Article

A panel at the ACI 10th Summit on Biosimilars focused on the recent FDA decision around the naming of biosimilar products and what that means for the industry, as well as related issues.

Comparing the Economics of Biosimilars and Generics

June 25, 2019

Article

The first set of presentations on day 2 of the ACI 10th Summit on Biosimilars on Tuesday in New York City reviewed the economics of biosimilar drugs and considerations for access, pricing, and reimbursement.

When Can Biologic Patent Disputes Go Before the ITC?

June 25, 2019

Article

Under which situations might the International Trade Commission (ITC) be the right choice for biosimilar patent disputes instead of federal district court? A panel discussed these questions at the ACI 10th Summit on Biosimilars on Monday in New York City.

x